drugset / Trial / NCT03671174

Summary

Undifferentiated connective tissue diseases (UCTD) are known to increase the risk of pregnancy morbidities, including recurrent pregnancy loss. However, there is no consensus or guideline about the treatment for recurrent pregnancy loss in UCTD patients. Therefore, based on the tendency to thrombosis formation and placental inflammation in the pathogenesis of UCTD, this trial proposes to evaluate the effect of hydroxychloroquine with or without prednisone combined with anticoagulation on pregnancy outcomes in recurrent pregnancy loss patients with UCTD.

Timeline

Start
2019-08-02
Primary completion
2021-09
Completion
2023-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 100 mg Oral
Subject Hydroxychloroquine Small molecule 200 mg Oral
Subject Prednisone Other / unclassified 10 mg Oral
Background Aspirin Small molecule 50 mg Oral
Background Dalteparin sodium Other / unclassified 5000 iu Subcutaneous
Background Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Background Nadroparin Calcium Other / unclassified 4100 iu Subcutaneous